Skip to main content

Table 3 Clinical parameters of chronically HIV-infected subjects under long-term viral suppressive ART (CI on ART)

From: Impaired Th17 polarization of phenotypically naive CD4+ T-cells during chronic HIV-1 infection and potential restoration with early ART

Subjects CD4 counts 1 Nadir CD4 counts 1 CD8 counts 1 Plasma viral load 2 Time since infection 3 ART ART initiation 4 Age 5
CI 01 463 36 757 50 152 3TC-Efavirenz 105 52
CI 02 n.a. 350 n.a. 50 94 Kivexa-Efavirenz 24 30
CI 03 616 486 330 40 186 Truvada-Viracept 153 29
CI 04 651 219 409 40 76 Kivexa-Nevirapine 19 39
CI 05 358 231 283 40 155 Atripla 142 48
CI 06 748 20 964 40 165 Truvada-Norvir-Reyataz 134 50
CI 07 517 223 259 40 82 Kivexa-Sustiva 39 35
CI 08 269 263 282 50 n.a. n.a. n.a. 47
CI 09 569 299 462 50 111 Darunavir-Raltegravir 105 50
CI 10 391 181 620 50 165 Dalavirdine-Kivexa 34 46
CI 11 847 110 944 40 168 Reyataz-Kivexa 116 62
CI 12 498 201 531 40 213 Darunavir-Raltegravir-Intelence-Ritonavir 155 62
CI 13 833 486 445 40 213 Truvada-Isentress 212 31
CI 14 886 301 579 40 60 Truvada-Isentress 15 54
CI 15 824 251 900 40 58 Atripla 11 31
CI 16 617 24 1,272 40 157 Kivexa-Efavirenz 3 54
CI 17* 776 407 478 40 289 Atripla 231 24
CI 18 277 228 909 40 11 Complera 2 23
CI 19 459 n.a 545 40 215 n.a. n.a. 48
Median 592 230 538 40 156 Yes 105 47
  1. 1, cells/μl; 2, HIV RNA copies per ml plasma (log10); 3, months; ART, antiretroviral therapy; 4, months post-infection; 5, years; n.a., information not available on ART duration and regimen; *, subject infected at birth.